Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

TRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT00203502.

Bibliographic Details
Main Authors: Ping-Ching Hsu, Susan A Kadlubar, Eric R Siegel, Lora J Rogers, Valentina K Todorova, L Joseph Su, Issam Makhoul
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0230248

Internet

https://doi.org/10.1371/journal.pone.0230248

Similar Items